Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Feb;41(2):242–250. doi: 10.1128/aac.41.2.242

Clinically used antimicrobial drugs against experimental pneumocystosis, singly and in combination: analysis of drug interactions and efficacies.

P D Walzer 1, J Runck 1, S Orr 1, J Foy 1, P Steele 1, M White 1
PMCID: PMC163696  PMID: 9021174

Abstract

We analyzed single drugs and combinations of drugs used clinically in the treatment of opportunistic infections and other conditions for their activities against Pneumocystis carinii pneumonia in immunosuppressed rats. When they were used alone, atovaquone, rifabutin, and dapsone were more active than clarithromycin or trimethoprim. Drug combinations were evaluated for synergistic activity by an analysis of variance model for two-way factorial experiments and a response surface model. Atovaquone combined with trimethoprim trimethoprim and some combinations of dapsone and clarithromycin was synergistic; however, the activities of combinations of atovaquone and rifabutin, atovaquone and clarithromycin, and atovaquone and dapsone were simply additive. Lovastatin, which inhibits 3-hydroxy-methylglutaryl coenzyme A reductase, was inactive whether it was used alone or in combination with other agents. None of the synergistic drug combinations was as effective as trimethoprim-sulfamethoxazole. We conclude that the rat model can be used to test combinations of anti-P. carinii agents for synergistic activity by well-established statistical techniques. While some combinations of clinically used antimicrobial drugs have enhanced anti-P. carinii activity, further studies are needed before clinical trials can be contemplated.

Full Text

The Full Text of this article is available as a PDF (258.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alder J., Mitten M., Shipkowitz N., Hernandez L., Hui Y. H., Marsh K., Clement J. Treatment of experimental Pneumocystis carinii infection by combination of clarithromycin and sulphamethoxazole. J Antimicrob Chemother. 1994 Feb;33(2):253–263. doi: 10.1093/jac/33.2.253. [DOI] [PubMed] [Google Scholar]
  2. Araujo F. G., Slifer T., Remington J. S. Rifabutin is active in murine models of toxoplasmosis. Antimicrob Agents Chemother. 1994 Mar;38(3):570–575. doi: 10.1128/aac.38.3.570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bartlett M. S., Queener S. F., Shaw M. M., Richardson J. D., Smith J. W. Pneumocystis carinii is resistant to imidazole antifungal agents. Antimicrob Agents Chemother. 1994 Aug;38(8):1859–1861. doi: 10.1128/aac.38.8.1859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Black J. R., Feinberg J., Murphy R. L., Fass R. J., Carey J., Sattler F. R. Clindamycin and primaquine as primary treatment for mild and moderately severe Pneumocystis carinii pneumonia in patients with AIDS. Eur J Clin Microbiol Infect Dis. 1991 Mar;10(3):204–207. doi: 10.1007/BF01964465. [DOI] [PubMed] [Google Scholar]
  5. Brun-Pascaud M., Chau F., Garry L., Jacobus D., Derouin F., Girard P. M. Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model. Antimicrob Agents Chemother. 1996 Sep;40(9):2067–2070. doi: 10.1128/aac.40.9.2067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chen G. Z., Foster L., Bennett J. L. Antischistosomal action of mevinolin: evidence that 3-hydroxy-methylglutaryl-coenzyme a reductase activity in Schistosoma mansoni is vital for parasite survival. Naunyn Schmiedebergs Arch Pharmacol. 1990 Oct;342(4):477–482. doi: 10.1007/BF00169467. [DOI] [PubMed] [Google Scholar]
  7. Clarkson A. B., Jr, Sarić M., Grady R. W. Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1990 Sep;34(9):1833–1835. doi: 10.1128/aac.34.9.1833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Comley J. C., Sterling A. M. Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice. Antimicrob Agents Chemother. 1995 Apr;39(4):806–811. doi: 10.1128/aac.39.4.806. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Frenkel J. K., Good J. T., Shultz J. A. Latent Pneumocystis infection of rats, relapse, and chemotherapy. Lab Invest. 1966 Oct;15(10):1559–1577. [PubMed] [Google Scholar]
  10. González-Ruiz A., Haworth S. J., O'Neil A. B., Warhurst D. C. Dapsone in low doses prevents Pneumocystis carinii pneumonia in the rat model. J Infect. 1991 Mar;22(2):143–152. doi: 10.1016/0163-4453(91)91547-b. [DOI] [PubMed] [Google Scholar]
  11. Greco W. R., Bravo G., Parsons J. C. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev. 1995 Jun;47(2):331–385. [PubMed] [Google Scholar]
  12. Guay D. R., Patterson D. R., Seipman N., Craft J. C. Overview of the tolerability profile of clarithromycin in preclinical and clinical trials. Drug Saf. 1993 May;8(5):350–364. doi: 10.2165/00002018-199308050-00003. [DOI] [PubMed] [Google Scholar]
  13. Hughes W. T., Killmar J. T., Oz H. S. Relative potency of 10 drugs with anti-Pneumocystis carinii activity in an animal model. J Infect Dis. 1994 Oct;170(4):906–911. doi: 10.1093/infdis/170.4.906. [DOI] [PubMed] [Google Scholar]
  14. Hughes W. T., Smith B. L. Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother. 1984 Oct;26(4):436–440. doi: 10.1128/aac.26.4.436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kaneshiro E. S., Ellis J. E., Jayasimhulu K., Beach D. H. Evidence for the presence of "metabolic sterols" in Pneumocystis: identification and initial characterization of Pneumocystis carinii sterols. J Eukaryot Microbiol. 1994 Jan-Feb;41(1):78–85. doi: 10.1111/j.1550-7408.1994.tb05938.x. [DOI] [PubMed] [Google Scholar]
  16. Kim C. K., Foy J. M., Cushion M. T., Stanforth D., Linke M. J., Hendrix H. L., Walzer P. D. Comparison of histologic and quantitative techniques in evaluation of therapy for experimental Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1987 Feb;31(2):197–201. doi: 10.1128/aac.31.2.197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kluge R. M., Spaulding D. M., Spain A. J. Combination of pentamidine and trimethoprim-sulfamethoxazole in therapy of Pneumocystis carinii pneumonia in rats. Antimicrob Agents Chemother. 1978 Jun;13(6):975–978. doi: 10.1128/aac.13.6.975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lee B. L., Medina I., Benowitz N. L., Jacob P., 3rd, Wofsy C. B., Mills J., 5th Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions. Ann Intern Med. 1989 Apr 15;110(8):606–611. doi: 10.7326/0003-4819-110-8-606. [DOI] [PubMed] [Google Scholar]
  19. Lorenz R. T., Parks L. W. Effects of lovastatin (mevinolin) on sterol levels and on activity of azoles in Saccharomyces cerevisiae. Antimicrob Agents Chemother. 1990 Sep;34(9):1660–1665. doi: 10.1128/aac.34.9.1660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Masur H. Prevention and treatment of pneumocystis pneumonia. N Engl J Med. 1992 Dec 24;327(26):1853–1860. doi: 10.1056/NEJM199212243272606. [DOI] [PubMed] [Google Scholar]
  21. Nollstadt K. H., Powles M. A., Fujioka H., Aikawa M., Schmatz D. M. Use of beta-1,3-glucan-specific antibody to study the cyst wall of Pneumocystis carinii and effects of pneumocandin B0 analog L-733,560. Antimicrob Agents Chemother. 1994 Oct;38(10):2258–2265. doi: 10.1128/aac.38.10.2258. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Queener S. F., Bartlett M. S., Richardson J. D., Durkin M. M., Jay M. A., Smith J. W. Activity of clindamycin with primaquine against Pneumocystis carinii in vitro and in vivo. Antimicrob Agents Chemother. 1988 Jun;32(6):807–813. doi: 10.1128/aac.32.6.807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Romand S., Pudney M., Derouin F. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii. Antimicrob Agents Chemother. 1993 Nov;37(11):2371–2378. doi: 10.1128/aac.37.11.2371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sturgill M. G., Rapp R. P. Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles. Ann Pharmacother. 1992 Sep;26(9):1099–1108. doi: 10.1177/106002809202600912. [DOI] [PubMed] [Google Scholar]
  25. Tidwell R. R., Jones S. K., Naiman N. A., Berger L. C., Brake W. B., Dykstra C. C., Hall J. E. Activity of cationically substituted bis-benzimidazoles against experimental Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1993 Aug;37(8):1713–1716. doi: 10.1128/aac.37.8.1713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Urbina J. A., Lazardi K., Marchan E., Visbal G., Aguirre T., Piras M. M., Piras R., Maldonado R. A., Payares G., de Souza W. Mevinolin (lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob Agents Chemother. 1993 Mar;37(3):580–591. doi: 10.1128/aac.37.3.580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Walzer P. D., Foy J., Runck J., Steele P., White M., Klein R. S., Otter B. A., Sundberg R. J. Guanylhydrazones in therapy of Pneumocystis carinii pneumonia in immunosuppressed rats. Antimicrob Agents Chemother. 1994 Nov;38(11):2572–2576. doi: 10.1128/aac.38.11.2572. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Walzer P. D., Foy J., Steele P., Kim C. K., White M., Klein R. S., Otter B. A., Allegra C. Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1992 Sep;36(9):1935–1942. doi: 10.1128/aac.36.9.1935. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Walzer P. D., Foy J., Steele P., White M. Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis. Antimicrob Agents Chemother. 1993 Jul;37(7):1436–1443. doi: 10.1128/aac.37.7.1436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Walzer P. D., Foy J., Steele P., White M. Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. Antimicrob Agents Chemother. 1992 Sep;36(9):1943–1950. doi: 10.1128/aac.36.9.1943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Walzer P. D., Kim C. K., Foy J. M., Linke M. J., Cushion M. T. Inhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1988 Jan;32(1):96–103. doi: 10.1128/aac.32.1.96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Yasuoka A., Oka S., Komuro K., Shimizu H., Kitada K., Nakamura Y., Shibahara S., Takeuchi T., Kondo S., Shimada K. Successful treatment of Pneumocystis carinii Pneumonia in mice with benanomicin A (ME1451). Antimicrob Agents Chemother. 1995 Mar;39(3):720–724. doi: 10.1128/AAC.39.3.720. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES